Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients
暂无分享,去创建一个
A. Cohen-Solal | F. Roubille | J. Januzzi | J. Cautela | N. Girerd | A. Théron | J. Tartière | T. Tibi | A. Bellemain‐Appaix | J. Tartiere
[1] J. McMurray,et al. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction , 2020, JACC. Heart failure.
[2] L. Rohde,et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. , 2019, European heart journal.
[3] D. DeMets,et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age , 2019, Circulation.
[4] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[5] E. Lonn,et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study , 2019, European journal of heart failure.
[6] P. Ponikowski,et al. Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry , 2019, European journal of heart failure.
[7] E. Braunwald,et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.
[8] Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[9] Thomas Kahan,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.
[10] M. Kamalesh,et al. Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure. , 2018, The American journal of cardiology.
[11] C. Torp‐Pedersen,et al. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study , 2018, Europace.
[12] G. Lip,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[13] D. Prabhakaran,et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial , 2018, JAMA.
[14] W. Tang,et al. Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low , 2018, Acta cardiologica.
[15] Akshay S. Desai,et al. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impa , 2018, Circulation. Heart failure.
[16] R. Wachter,et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up‐titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study , 2018, European journal of heart failure.
[17] A. Mebazaa,et al. Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. , 2017, JACC. Heart failure.
[18] L. Rohde,et al. Rational and design of a randomized, double‐blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC‐1 trial , 2017, American heart journal.
[19] Gerasimos S Filippatos,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.
[20] S. Solomon,et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF , 2017, European heart journal.
[21] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[22] Akshay S. Desai,et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial , 2016, European journal of heart failure.
[23] Akshay S. Desai,et al. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial , 2016, Circulation. Heart failure.
[24] R. Wachter,et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens , 2016, European journal of heart failure.
[25] P. Ponikowski,et al. Physicians' adherence to guideline‐recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey , 2016, European journal of heart failure.
[26] R. Wachter,et al. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. , 2016, JACC. Heart failure.
[27] Fabrizio Ricci,et al. Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. , 2015, Journal of the American College of Cardiology.
[28] J. McMurray,et al. Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. , 2015, European heart journal.
[29] A. Bagriy,et al. Addition of Ivabradine to β-Blocker Improves Exercise Capacity in Systolic Heart Failure Patients in a Prospective, Open-Label Study , 2015, Advances in Therapy.
[30] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[31] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[32] Karl Swedberg,et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.
[33] K. Swedberg,et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. , 2013, American heart journal.
[34] K. Swedberg,et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. , 2012, Journal of the American College of Cardiology.
[35] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[36] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[37] K. Dickstein,et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.
[38] D. Mozaffarian,et al. The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.
[39] A. Cohen-Solal,et al. Interaction between pulse wave velocity, augmentation index, pulse pressure and left ventricular function in chronic heart failure , 2006, Journal of Human Hypertension.
[40] D. Roffman. High- Versus Low-Dose ACE Inhibitor Therapy in Chronic Heart Failure , 2004, The Annals of pharmacotherapy.
[41] J. Rouleau,et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. , 2004, Journal of the American College of Cardiology.
[42] A. Burger,et al. Relation between pulse pressure and survival in patients with decompensated heart failure. , 2004, The American journal of cardiology.
[43] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[44] M. Pfeffer,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.
[45] B. Pitt,et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[46] B. Pitt,et al. EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .
[47] N. Hollenberg,et al. Literature alert , 2002 .
[48] P. Vandervoort,et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. , 2002, Journal of the American College of Cardiology.
[49] J. Cohn,et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.
[50] R Dietz,et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.
[51] M. D. De Buyzere,et al. Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS) , 2000, Acta cardiologica.
[52] P A Poole-Wilson,et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.
[53] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[54] J. Schwartz,et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.
[55] K. Adams,et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.
[56] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[57] M B Weiss,et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. , 1996, American heart journal.
[58] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.